BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Opinion: Reexamination of Failed DMD Trial a Much-Needed Reckoning for FibroGen

  A thorough reassessment of the confounders between FibroGen’s trials is necessary to salvage the company’s Duchenne Muscular Dystrophy program and regain investor confidence.

  September 7, 2023

   · 

  2 min read

   · 

  Jia Jie Chen
• 

  Drug Development

  CymaBay’s Liver Disease Candidate Hits Phase III Primary, Secondary Endpoints

  Analysts said CymaBay’s seladelpar is emerging as the “therapy of choice in the second-line setting” and “could impact the treatment landscape” across a spectrum of primary biliary cholangitis patients.

  September 7, 2023

   · 

  2 min read

   · 

  Connor Lynch
• 

  Policy

  BMS Accused by HMO of Patent Fraud to Allegedly Sustain Pomalyst Monopoly

  Blue Cross and Blue Shield of Louisiana has filed a case against Bristol Myers Squibb alleging the company conducted patent fraud to extend protections for its multiple myeloma drug Pomalyst.

  September 7, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  J&J Terminates Phase III Study of Cardio Asset in Pulmonary Hypertension

  At the recommendation of an independent data monitoring committee, J&J decided to stop the MACiTEPH trial in chronic thromboembolic pulmonary hypertension due to futility.

  September 7, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Astellas Withdraws IRA Lawsuit After Xtandi Avoids Drug Price Negotiations

  The company has withdrawn a suit against the Department of Health and Human Services after its prostate cancer therapy was not included in Medicare’s initial drug price negotiation list.

  September 7, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  FDA Action Alert: GSK and Alnylam

  After a three-month delay, GSK expects an FDA verdict for its myelofibrosis candidate, while Alnylam gears up for an advisory committee meeting discussing patisiran in cardiomyopathy of ATTR amyloidosis.

  September 7, 2023

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win

  The RNAi therapy, which the companies are co-developing and commercializing, reduced blood pressure in hypertensive patients with high cardiovascular risk by 15 mmHg over placebo.

  September 7, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• Genetown

  Scientists detail current evidence that Long COVID is caused by persistent SARS-CoV-2 viral reservoirs

  PolyBio Research Foundation is excited to announce a new publication in the journal Nature Immunology.

  September 7, 2023

   · 

  2 min read
• Pharm Country

  West to Participate in Upcoming September 2023 Investor Conference

  West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will present at Bank of America Global Healthcare Conference in London, UK on Thursday, September 14, 2023 at 10:50 AM BST.

  September 7, 2023

   · 

  1 min read
• BioForest

  NanoString Expands Partnerships with Contract Research Organizations Making Spatial Molecular Imaging Tools Widely Available to Global BioPharma Researchers

  NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced three new Contract Research Organization CosMxTM Spatial Molecular Imager partnerships.

  September 7, 2023

   · 

  3 min read